1 Adiposity, metabolites and endometrial cancer risk: Mendelian randomization and Observational

- 2 analyses
- 3 Matthew A Lee^{1,2,3*}, Vanessa Y. Tan^{1,2*}, Dimitri J Pournaras⁴, Sabrina Wang³, Laure Dossus³, Marc J.
- 4 Gunter^{3,5}, Kaitlin H. Wade^{1,2}, Laura J. Corbin^{1,2}, Nicholas J. Timpson^{1,2}
- ⁵ ^{*}These authors contributed equally to this work
- ⁶ ¹Medical Research Council (MRC) Integrative Epidemiology Unit, Population Health Sciences, Bristol
- 7 Medical School, University of Bristol, Bristol, United Kingdom.
- 8 ²Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
- ⁹ International Agency for Research on Cancer, World Health Organization, Lyon, France
- ⁴Department of Upper GI and Bariatric/Metabolic Surgery, North Bristol NHS Trust, Southmead Hospital,
- 11 Bristol, UK.
- ¹²⁵Cancer Epidemiology and Prevention Research Unit, School of Public Health, Imperial College London,
- 13 United Kingdom.
- 14
- 15 Corresponding author: Professor Nicholas J. Timpson, Address: MRC Integrative Epidemiology Unit,
- 16 University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, email: N.J.Timpson@bristol.ac.uk
- 17 Key words: Adiposity, Metabolites, Endometrial cancer, Mendelian randomization
- 18 Main text words: 4,279; Abstract: 417; References: 55; Tables & Figures: 9; Supplementary files: 4

19 Abstract

20 Introduction

Increased and excess adiposity is associated with increased risk of endometrial cancer (EC) and both of these are associated with circulating metabolite profiles. However, how metabolites relate to the adiposity-EC relationship remains unclear.

24

25 Methods

26 We have brought together evidence from Mendelian randomization (MR) and observational 27 analyses to evaluate the effect of i) adiposity traits on endometrial cancer, ii) adiposity traits 28 on circulating metabolites and iii) adiposity-associated metabolites on EC. We have also 29 evaluated the potential role of metabolites in the adiposity-EC relationship using 30 multivariable MR. Observational analyses were conducted using individual level data from UK 31 Biobank (N = 1,005 cases and 215,339 controls). MR analyses were performed using female-32 specific summary statistics from genome-wide association studies of body mass index (BMI; 33 N up to 434,794), waist-to-hip ratio (WHR; N up to 381,152), 249 metabolites and ratios from 34 targeted nuclear magnetic resonance metabolomics (N up to 140,768) and EC risk (12,906 35 cases and 108,979 controls).

36

37 Results

38 In observational analyses, higher BMI and WHR were associated with elevated odds of overall 39 EC (odds ratio (OR) per standard deviation (SD) increase in BMI = 1.37; 95% confidence 40 interval (CI) = 1.19, 1.57; OR per SD increase in WHR= 1.15; 95% CI = 1.01, 1.32). In MR 41 analysis, higher BMI was associated with elevated odds of overall EC risk (OR per SD increase 42 in BMI = 1.80; 95% CI = 1.56, 2.07), endometrioid cancer (OR = 1.71; 95% CI = 1.45, 2.02) and 43 non-endometrioid cancer (OR = 2.20; 95% CI = 1.55, 3.12). There was weaker evidence for a 44 causal relationship with WHR. BMI was associated with 165 metabolites and ratios after 45 Bonferroni-correction in MR analyses, several of which were associated with EC and 25 of 46 which were directionally consistent with an intermediate role in the effect of BMI on EC risk 47 from two-step MR and observational analyses. In MVMR analyses, there was evidence 48 suggesting that the effect of BMI on non-endometrioid EC was mediated by several lipid 49 metabolites; for example, the univariable MR OR for non-endometrioid EC per 1 SD increase

- in BMI was 2.51 (95%CI = 1.47, 4.29), whereas on adjusting for free cholesterol to total lipids
 ratio in medium LDL, the MVMR OR for non-endometrioid EC per 1 SD increase in BMI was
 1.18 (95%CI = 0.53, 2.66). Further bioinformatic analyses highlighted a mixture of other
 potential shared pathways (including height, adiposity traits and blood cell traits) that could
 influence the risk of EC.
- 55

56 Conclusion

57 Evidence here suggests that higher BMI causes a higher risk of overall and all histological 58 subtypes of EC and variation in numerous circulating metabolites. Several of these 59 metabolites showed relationships consistent with an intermediate role between BMI and 60 non-endometrioid EC, however, further bioinformatic analyses highlighted other potential 61 shared mechanisms that could influence the risk of EC.

- 62
- 63
- 64
- 65
- 66
- 67
- 68

69 Introduction

Endometrial cancer (EC; cancer of the lining of the uterus) is the most common gynaecological cancer among women with more than 380,000 new cases diagnosed globally¹. Based on differences in histology and clinical outcomes, there are two main subtypes of EC: endometrioid carcinomas (type 1 tumours) with good prognosis and non-endometrioid carcinomas (type 2 tumours) with worse prognosis². Endometrioid EC is more commonly hormonally driven compared with non-endometrioid EC³.

76

Excess body weight is robustly associated with EC, with support from observational studies⁴. Mendelian randomisation⁵ (MR) studies, which use genetic variants as instruments (or proxies), of adiposity traits further support the evidence base for a causal relationship with EC^{6–8}. However, whilst the relationship between adiposity and EC is well-established, understanding of the mechanisms and covariables involved in the adiposity-EC relationship remains incomplete. Furthermore, evidence of associations between body fat distribution, measured as waist-hip-ratio (WHR), has only been supported with observational studies^{4,6,8}.

84

85 Metabolic reprogramming is recognised as a hallmark of tumorigenesis⁹ and there is evidence that metabolic dysfunction drives the development and progression of EC^{10,11}. Findings from 86 87 a recent prospective study suggest that concentrations of glycine, serine, sphingomyelin and free carnitine may represent specific pathways involved in EC development¹². Increased 88 89 adiposity causes changes to an individual's systemic metabolic profile^{13–15}. Observational and 90 MR studies support an effect of adiposity (proxied using body mass index [BMI]), on raised 91 amino acids, fatty acids and inflammatory glycoprotein acetyls¹⁵, leading to suggestions that 92 a potential mechanism linking adiposity and EC could be adiposity-induced metabolic changes¹⁰. A recent prospective study showed that EC is positively associated with adiposity-93 associated metabolic changes including specific amino acids and lipids¹⁶; however, whether 94 95 these relationships are causal is unclear.

96

We aimed to better understand the potential role of circulating metabolites as intermediatesin the association between adiposity and EC risk by triangulating evidence from summary-

99 level univariable two-step¹⁷ MR and multivariable MR approaches in combination with
100 observational analyses in UK Biobank.

101

102 Methods

103 Analytical strategy

104 This study has four main analyses that were performed sequentially (Figure 1) to estimate: 105 (Part I) the effect of adiposity measures on EC, (Part II) the effect of adiposity measures on 106 circulating metabolites, (Part III) the effect of adiposity-associated metabolites on EC, and 107 (Part IV) the potential intermediate role of adiposity-associated metabolites in the 108 relationship between adiposity and EC (identified in Part II and III). Observational analyses 109 were performed for Parts I-III. MR analyses were performed for Parts I-IV; Metabolite data 110 from UK Biobank were used in both the MR and observational analyses. This study is reported 111 as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and STROBE-MR guidelines (Supplementary Table S1 and S2)^{18,19}. 112

113

114 **Observational analyses (Part I-III)**

115 Study population

116 UK Biobank is a nation-based health project that recruited more than 500,000 participants (aged 37-73 years, 56.3% were women) between 2006 and 2020^{20,21}. In addition to the 117 118 collection of biological samples (blood, saliva and urine), health, demographic and 119 anthropometric data were collected in 22 assessment facilities across England, Wales and 120 Scotland²². Participants provided written informed consent. Ethical approval was obtained 121 from the Northwest Multi-centre Research Ethics Committee (11/NW/0382). Data from UK 122 Biobank were accessed via application number 16391 and 30418. Data for adiposity measures 123 and endometrial cancer outcome was extracted on the 08/07/2021 and the ¹H-NMR 124 metabolite data was extracted on the 08/02/2023.

125

126 Adiposity measures

BMI was calculated as weight (kg)/height² (m²) and WHR as waist circumference (cm)/hip circumference (cm). Height was measured to the nearest centimetre, using a Seca 202 stadiometer, and body weight to the nearest 0.1kg, using a Tanita BC-418 body composition

analyser. Waist circumference was measured at the natural indent (the umbilicus was used if
 the natural indent could not be observed); hip circumference was measured at the widest
 part of the hips. BMI and WHR were inverse rank normal transformed prior to observational
 analyses and represent normalised SD units.

134

135 <u>Metabolite measures</u>

136 Non-fasting EDTA plasma samples were collected from approximately 275,000 participants, a random subset of the original ~500,000, who provided samples at the 2006-2010 assessment 137 138 (N=275,000) or at a subsequent assessment in 2012-2013 (N=17,000) (around 15,000 of these 139 have both baseline and repeat assessment). A total of 249 metabolic traits (168 140 concentrations plus 81 ratios) were quantified using ¹H-NMR spectroscopy (data pre-141 processing and quality control steps conducted by Nightingale Health are described 142 previously^{23,24}). Inverse rank normal transformed metabolite concentrations were used in all 143 analyses and represent normalised SD units.

144

145 <u>Endometrial cancer</u>

146 EC was defined as a malignant neoplasm of the endometrium. The UK Biobank database 147 contained a record of all cancers including their subtype occurring either before or after participant enrolment using the International Classification of Diseases, 9th and 10th revision 148 149 (ICD-10, ICD-9). The following ICD-10 and ICD-9 codes were used to define EC: ICD10 codes 150 (C540, C541, C542, C543, C549 and C55) and ICD9 codes (179, 1799, 180, 182, 1820, 1821 and 151 1828). Cases were characterised as incident or prevalent using 'age when they attended the 152 centre' and 'age when first reported EC cancer'. Participants were defined as incident cases if 153 their 'attending age' was less than their 'cancer diagnosis age'. In total, there were 1,935 EC 154 cases with 1,005 being incident cases and 930 prevalent cases. Only incident cases (N=1,005) 155 were included in our analyses. Controls (n=215,339) were defined as female participants who 156 had no record of any type of cancer, in-situ carcinoma, or an undefined neoplasm.

157

158 <u>Covariables</u>

159 We included potential confounders of the BMI-metabolite-EC relationships in our analyses.

160 The potential confounders were sociodemographic factors (age at assessment, physical

activity, smoking status, alcohol consumption and educational attainment) and femalespecific factors (history of hormone replacement therapy (HRT) use, age at first live birth, age at last live birth, age at menarche and menopausal status). Age, smoking status, alcohol consumption, education attainment and female-specific factors were self-reported at the baseline assessment by questionnaire. Physical activity level over a typical week was selfreported using the International Physical Activity Questionnaire and reported as metabolic equivalent of task (MET) per week.

168

169 Statistical analyses

170 Observational associations between: I) adiposity measures and EC (Figure 1, Part I) were 171 assessed using multivariable logistic regression, II) adiposity measures and metabolites 172 (Figure 1, Part II) were assessed using multivariable linear regression for cases and controls 173 combined in one cohort and III) adiposity-associated metabolites and EC (Figure 1, Part III) 174 were assessed using multivariable logistic regression. All analyses were initially adjusted for 175 age at assessment and centre. Models were additionally adjusted for potential confounders 176 (smoking status, alcohol consumption, education status, physical activity, hormone 177 replacement therapy use, age at first live birth, age at last live birth, age at menarche and 178 menopausal status). To account for multiple testing, we used the Bonferroni-adjusted p value 179 threshold (0.05/249) for the association between adiposity measures and metabolites and p-180 value < 0.05 for all other tests. Multivariable linear and logistic regression analyses were 181 performed using the Im and glm functions, respectively, in R.

182

183 Genome-wide association study results and Mendelian randomisation analyses (Part I-IV)

184 Data sources and study populations

185 Adiposity instruments

We identified single nucleotide polymorphisms (SNPs) that were independently associated (low linkage disequilibrium (LD), R²<0.001) with BMI and WHR (unadjusted for BMI) at $p < 5 \times 10^{-1}$ ⁹ from a recent large-scale female-specific genome-wide association study (GWAS) metaanalysis of 434,794 female adults of European ancestries from the Genetic Investigation of Anthropometric Traits (GIANT) consortium and the UK Biobank²⁵ (**Supplementary Table 3**). Adiposity measures were inverse rank normal transformed prior to genome-wide analysis and

units therefore represent a normalised standard deviation (SD). In total, 271 (average Fstatistic = 41) and 227 (average F-statistic = 45) SNPs were identified for BMI and WHR, respectively.

195

196 Metabolite GWAS in UK Biobank and selection of metabolite instruments

197 A random subset of non-fasting baseline plasma samples, consisting of 275,000 UK Biobank 198 participants and 17,000 repeat-visit samples (around 15,500 of these have both a baseline 199 and repeat assessment), were measured using targeted high-throughput ¹H-Nuclear magnetic resonance (¹H-NMR) metabolomics (Nightingale Health Ltd; biomarker 200 201 quantification version 2020)^{24,26}. Genotype data was available for 488,377 individuals, of 202 which 49,979 were genotyped using the UK BiLEVE array and 438,398 using the UK Biobank 203 axiom array. Pre-imputation QC, phasing and imputation have been described previously²¹. 204 Genotype imputation was performed using IMPUTE2 algorithms²⁷ to a reference set combining the UK 10K haplotype and HRC reference panels²⁸. Post-imputation QC was 205 206 performed as described in the "UK Biobank Genetic Data: MRC-IEU Quality Control" 207 documentation^{29,30}. We conducted a female-specific GWAS for the 249 ¹H-NMR-derived 208 metabolites and ratios in UK Biobank female participants of European descent (N=140,768) 209 using the MRC IEU UK Biobank GWAS pipeline³⁰. We restricted the samples to individuals of 210 European ancestry as defined by the largest cluster in an in-house k-means clustering of 211 genetic ancestry data (K=4) after standard exclusions including withdrawn consent, mismatch 212 between genetic and reported sex and putative sex chromosome aneuploidy²⁹⁻³¹ 213 (Supplementary Table 3). Metabolite measures were inverse rank normal transformed prior 214 to genome-wide analysis and units therefore represent a normalised SD. Genome-wide 215 association analysis was conducted using a linear mixed model (LMM) as implemented in BOLT-LMM (v2.3)³². Population structure was modelled using 143,006 directly genotyped 216 217 SNPs (MAF > 0.01; genotyping rate > 0.015; Hardy-Weinberg equilibrium p-value < 0.0001 and 218 LD pruning to an r2 threshold of 0.1 using PLINK(v2.00)). Genotype array and fasting time 219 were adjusted for in the model. We identified 11-167 independent SNPs (r²<0.001 and p<5x10⁻⁸) for each of the ¹H-NMR-derived metabolites (average F-statistics: ranged from 40.6-220 221 81.6).

222

223 Endometrial Cancer GWAS data

We obtained SNP estimates from the largest GWAS (as log odds ratio (OR)) for EC to date⁸, 224 225 including up to 12,906 cases and 108,979 controls from 13 studies (Supplementary Table 3). 226 Of the 12,906 cases and 108,979 controls, 636 cases (5%) and 62,853 controls (58%) were 227 from UK Biobank. Summary statistics were also available for the association between genetic 228 variation and the EC subtypes, endometrioid (8,758 cases) and non-endometrioid (1,230 229 cases) cancer; both GWASs used the full set of controls (N = 108,979). None of the 230 endometrial subtype cases were from UK Biobank. Histological subtypes of EC were 231 confirmed based on pathology reports and detailed study descriptions have previously been 232 reported⁸.

233

234 Statistical analysis

In each instance, MR estimates are interpreted as the change in outcome per SD unit change
in exposure. Estimates for metabolite outcomes reflect SD unit change, and estimates for EC
outcomes reflect odds ratios (OR). All analyses were performed using R version 3.5.3³³.
Univariable MR analyses were performed using the TwoSampleMR (version 0.4.22) package²⁶.
Multivariable MR analyses were performed using the MVMR (version 0.3) package³².

240

241 First, we examined the association between BMI and WHR with overall, endometrioid and 242 non-endometrioid EC risk using summary-level data from female-specific GWAS of BMI, WHR 243 and EC (Figure 1, Part I). Details of the SNPs included in each analysis, and proxies used (where SNPs were not available in the outcome data), are provided in Supplementary Table 4. 244 245 Summary statistics were harmonised using the harmonise data function within the 246 TwoSampleMR R package (version 0.4.22)³³. Univariable causal estimates were combined 247 using the inverse-variance weighted (IVW) multiplicative random effects (IVW-MRE) model³⁴. Where possible (i.e., where there were three or more instruments), the assumption of no 248 pleiotropy among genetic instruments and outcomes were explored using MR-Egger³⁵, 249 weighted median³⁶ and weighted mode³⁷ estimators. These methods are sensitive to the 250 251 effects of potential pleiotropy under different assumptions. No p-value threshold 252 requirements were set for these methods and, instead, consistency between the IVW model 253 and the three sensitivity MR methods (MR-Egger, weighted median and weighted mode) was 254 assessed.

255

Second, adiposity traits (BMI and WHR) that showed evidence of an effect on EC with p values 256 257 < 0.05 from IVW-MRE models and with consistent associations across the three sensitivity MR 258 methods, were taken forward and examined for associations with the ¹H-NMR-measured 259 metabolites (Figure 1, Part II). Summary-level data were obtained from a female-specific 260 GWAS for adiposity traits and ¹H-NMR metabolites, and we examined the effect of adiposity 261 traits on ¹H-NMR-measured metabolites using the four MR models described above. Metabolites that were associated with the adiposity traits with p values < 0.05/249262 263 (Bonferroni-adjusted p-value threshold) from IVW-MRE models were taken forward and 264 examined for association with EC risk using IVW-MRE model (if ≥ 2) or Wald ratio (if 1 SNP) 265 (Figure 1, Part III).

266

Multivariable MR (MVMR)^{38,39} was conducted to test the hypothesis that adiposity-associated 267 268 metabolites (identified in Part II and III) may act as intermediate factors in the effect of BMI 269 on EC (Figure 1, Part IV). Only metabolites that showed a consistent direction of effect across 270 the adiposity-EC, adiposity-metabolite, and metabolite-EC analyses from both MR and 271 observational analyses (identified in Part II and III) were included in the MVMR analyses. For 272 the MVMR analyses, we fitted a model with BMI and EC and included each BMI-associated 273 metabolite in turn to estimate the direct causal effect of BMI on EC. We used female-specific 274 SNPs for BMI based on an earlier (lower-powered) GWAS⁴⁰ for the multivariable models to avoid a relative dilution of metabolite instrument strength⁴¹ given that the number of SNPs 275 276 for BMI from the latest BMI GWAS far outnumbered those for metabolites. Conditional F-277 statistics were used to evaluate instrument strength³⁹. Heterogeneity was quantified using an 278 adapted version of the Q statistic $(Q_{A_i}$ also a further modification of Cochran's Q)³⁹.

279

280 Sensitivity analyses

Sample overlap between exposure and outcome GWAS can bias MR estimates towards the confounded observational estimate (inflated type 1 error) in the presence of weak instrument bias in a manner proportional to the degree of overlap⁴². This bias can be inflated by "Winner's curse", in which weights for genetic instruments are derived from discovery samples that overlap with outcome samples. There was sample overlap across our MR analyses as the adiposity, ¹H-NMR metabolite and EC GWAS all included participants from UK Biobank. Given 287 the random selection of samples for metabolomics analysis and the inclusion of almost all 288 samples within the adiposity GWAS it is not possible to precisely quantify the degree of 289 sample overlap but we make the assumption of 100% sample overlap between the adiposity 290 and ¹H-NMR metabolite GWAS. There was also approximately 5% overlap for both the 291 adiposity and ¹H-NMR metabolite GWAS with the overall EC GWAS. Given this, we conducted sensitivity analyses to evaluate the influence of sample overlap in our MR analyses. First, for 292 293 analyses examining the association between adiposity traits with endometrial cancer risk 294 (Figure 1, Part I), we re-performed MR analyses using alternative GWAS data for BMI (n=171,977) and WHR (N=118,004) where there was no sample overlap^{40,43} with either the EC 295 296 GWAS conducted by ECAC⁸ or an alternative EC GWAS conducted by ECAC which excluded UK 297 Biobank participants (personal correspondence) (N for overall EC=12,270 cases and 46,126 298 controls; N for endometrioid EC=8,758 cases and 46,126 controls and N for non-endometrioid 299 EC = 1,230 cases and 35,447 controls)⁸. Second, for analyses examining the association 300 between adiposity traits with ¹H-NMR metabolites (Figure 1, Part II), we re-performed MR 301 analyses using alternative GWAS data for BMI where there was no sample overlap^{40,43}. Third, 302 for analyses examining the association between ¹H-NMR metabolites and endometrial cancer 303 risk (Figure 1, Part III), we re-performed MR analyses using the alternative GWAS for EC which 304 had excluded UK Biobank participants⁸ (Supplementary Table 3).

305

306 Examining off-target effects using PhenoScanner (Part V)

307 Due to the shared genetic architecture and pleiotropic nature of instruments for metabolites^{44–46}, it is possible for variants acting as proxies for metabolites to exert off-target 308 309 or pleiotropic effects on EC through other biological mechanisms. This presents the possibility 310 that intermediate associations are reflecting common, but unmeasured, biological 311 underpinnings rather than more obvious hypothesised pathway effects. To investigate this, 312 we assessed whether genetic instruments for adiposity- and EC-associated, (and apparently 313 intermediate) metabolites were associated with other traits (p < 1E-10) in a manner different 314 to that expected by chance given documented genotype/metabolite/trait associations. Using PhenoScanner^{47,48}, we assessed the co-association of adiposity- and EC-associated 315 316 metabolites with other phenotypes and outcomes before performing the same procedure 317 over 100 iterations, but for randomly selected metabolites taken from the 244 metabolites 318 not found to underlie the association between adiposity and EC risk. The overall profile of

- 319 these redraws were compared with that from the adiposity- and EC-associated instruments,
- 320 i.e. counts of detectable associations with trait domains for adiposity- and EC-associated
- 321 instruments versus SNPs associated with random metabolites.
- 322

323 Results

324 Population and data overview

The observational analyses within UK Biobank included up to 1,005 female participants who had a diagnosis of incident EC and up to 215,339 controls (**Table 1**). The cases and controls had a mean (SD) age of 59.63 (6.43) years and 55.83 (8.02) years, respectively. Mean BMI was higher among cases than controls (at 30.33kg/m² (7.07) and 27.06kg/m² (5.17), respectively). Mean WHR was higher among cases than controls (at 0.84 (0.07) and 0.82 (0.07), respectively). 3.66% reported having a diagnosis of diabetes, and this was more common among cases than controls (8.99% and 2.64%, respectively).

332

333 Association between adiposity measures and endometrial cancer (Part I)

334 For BMI, observational analyses showed evidence that higher BMI (per SD) was associated 335 with 1.61 (95% CI = 1.49, 1.75) times higher odds of overall EC; these results were consistent 336 when adjusting for all covariables (OR = 1.37; 95% CI = 1.19, 1.57) (Figure 2; Table 2). This was 337 supported by univariable MR analysis, which found that higher BMI (per SD) was associated 338 with 1.80 (95% confidence interval (CI) = 1.56, 2.07) times higher odds of overall EC using the 339 IVW-MRE model (Figure 2; Supplementary Table 5). Similar results were found for 340 endometroid cancer (OR = 1.71; 95% CI = 1.45, 2.02) and non-endometrioid cancer (OR = 2.20; 341 95% CI = 1.55, 3.12) (Supplementary Table 5). This finding was consistent across sensitivity 342 analyses using methods that consider potential genetic pleiotropy and when using 343 instruments from non-overlapping samples (Supplementary Table 5).

344

For WHR, observational analyses showed evidence that higher WHR (per SD) was associated with 1.23 (95% CI = 1.13, 1.34) times higher odds of overall EC; these results were consistent when adjusting for all covariables (OR = 1.15; 95% CI = 1.01, 1.32) (**Figure 2**; **Table 2**). Evidence of association between WHR (per SD) and overall EC (OR = 1.10; 95% CI = 0.93, 1.29), endometroid EC (OR = 1.09; 95% CI = 0.91, 1.30) and non-endometrioid EC (OR = 1.43; 95% CI

350 = 0.96, 2.12) in univariable MR was weaker (Figure 2; Supplementary Table 5). Sensitivity
 analyses were broadly consistent for overall and endometrioid EC. However, findings were
 less consistent for non-endometrioid EC in sensitivity analyses where the MR-Egger estimate
 (OR = 3.99; 95% Cl = 1.14; 13.95) was greater in magnitude compared to the IVW estimates
 (Supplementary Table 5) and when using instruments from non-overlapping samples (IVW
 OR= 1.93; 95% Cl = 1.17, 3.18) (Supplementary Table 5).

356

357 Association between adiposity measures and metabolites (Part II)

Higher BMI (per SD) was associated with 175 metabolites after correcting for multiple testing and using the IVW-MRE model (**Figure 3**; **Supplementary Table 6**). Of these metabolites, 165 had consistent directions of effect in all four MR models and the fully-adjusted observational analyses (**Supplementary Figure 1 and 2**; **Supplementary Table 7**) and were taken forward for subsequent analysis with EC. These findings were broadly consistent across sensitivity analyses using instruments from non-overlapping samples (r=0.94) (**Supplementary Table 6**).

365 BMI had a broad effect on the metabolomic profile, with associations across many metabolite 366 classes including numerous lipid metabolites and their ratios such as total cholesterol, total 367 lipids, triglycerides and cholesteryl esters in high density lipoprotein (HDL) and very low-368 density lipoprotein (VLDL). For example, higher BMI led to 0.40 SD (95% CI = 0.34, 0.46) and 369 0.39 SD (95% CI = 0.38, 0.39) lower levels of total cholesterol in very large HDL in MR and 370 observational analyses, respectively. There was also evidence that higher BMI increased levels 371 of several amino acids including valine, isoleucine, leucine, tyrosine, and phenylalanine 372 (Supplementary Table 6). For example, higher BMI led to 0.23 SD (95% CI = 0.19, 0.27) and 373 0.26 SD (95% CI = 0.25, 0.27) higher levels of valine in MR and observational analyses, 374 respectively.

375

376 Association between BMI-associated metabolites and endometrial cancer (Part III)

377 Of the 165 BMI-associated metabolites, 25 metabolites (representing 27 adiposity-378 metabolite-EC associations) were directionally consistent with an intermediate role in the 379 association between BMI and overall EC (2 associations), endometrioid EC (1 association) and 380 non-endometrioid EC (24 associations) from MR analyses (**Figure 4 and Supplementary Figure**

381 3; Supplementary Table 8). Observational analyses were only possible for overall EC. The two 382 BMI-associated metabolites (phospholipid to total lipids ratio in medium VLDL and cholesteryl 383 esters to total lipids ratio in medium HDL) had directions of effects consistent with MR 384 analyses in the fully adjusted observational analysis (Supplementary Table 9).

385

386 Of the 25 BMI-associated metabolites, 2 were associated with two EC outcomes in the MR 387 analyses: phospholipids to total lipids ratio in medium VLDL was associated with overall (OR 388 = 0.87; 95% CI = 0.75, 1.00) and endometrioid EC (OR = 0.85, 95% CI = 0.72, 0.99) and 389 cholesteryl esters to total lipids ratio in medium HDL was associated with overall (OR = 0.86, 390 95% CI = 0.75, 0.98) and non-endometrioid EC (OR = 0.61, 95% CI = 0.44, 0.85). The remaining 391 23 metabolites - mainly of the lipoprotein subclasses - were associated with just one EC 392 outcome, which was predominantly non-endometrioid cancer. For example, the largest 393 positive and negative effects were observed for the association between cholesteryl esters to 394 total lipids ratio in medium LDL (OR = 1.85; 95% CI = 1.15, 2.98) and total esterified cholesterol 395 (OR = 0.57; 95% CI = 0.36, 0.90) and non-endometrioid cancer using the IVW-MRE model 396 (Figure 4).

397

Examining the intermediate role of metabolites in the effect of adiposity on EC: Multivariable MR analyses (Part IV)

400 We used MVMR to investigate whether the 25 BMI-associated metabolites were potential 401 intermediates of the effect of BMI on EC risk. In MVMR, there was little evidence that the 402 association of BMI with overall and endometrioid EC was strongly attenuated following 403 adjustment for most metabolites (Figure 5). For non-endometrioid EC, the association of BMI 404 with non-endometrial cancer was attenuated following adjustment for various metabolites 405 (Figure 5); for example, the univariable MR OR for non-endometrioid EC per 1 SD higher BMI 406 was 2.51 (95%CI = 1.47, 4.29), whereas the MVMR OR for non-endometrioid EC per 1 SD 407 increase in BMI was 1.18 (95%CI = 0.53, 2.66) after adjusting for free cholesterol to total lipids 408 ratio in medium LDL. The conditional F statistics for BMI and metabolites instruments are 409 presented in Supplementary Table 10.

410

411 Examining off-target effects

412 Given the highly pleiotropic nature of the metabolite instruments, it is possible that the 413 instruments might be proxying other common, but unmeasured, biological pathways rather 414 than having a direct effect through the metabolites. Using a commonly used catalogue of 415 genetic association results (PhenoScanner^{47,48}), we conducted a phenome scan for the genetic 416 instruments proxying metabolites potentially underlying the adiposity-EC relationship and 417 compared the traits association profiles with those of randomly selected metabolites. We 418 identified a larger than expected proportion of instruments associated with several lipid traits 419 including HDL, LDL, triglycerides and total cholesterol, as well as anthropometric (height and 420 adiposity) and blood cell traits for the metabolites underlying the adiposity-EC relationship 421 compared to the randomly selected metabolites. This suggests that the metabolite 422 instruments could be proxying for or are a response read-out of other potentially shared 423 biological pathways (Figure 6).

424

425 **Discussion**

426 This study aimed to identify potential metabolic intermediates of the effects of adiposity on 427 EC risk using MR and observational analyses. Higher BMI increased risk of overall EC and EC 428 stratified by histological subtypes. BMI was associated with numerous metabolites; 25 of 429 which were also found to increase EC risk. There was evidence from both two-step and 430 multivariable MR analyses that the effect of BMI on EC was mediated strongly by several lipid 431 metabolites; however, further bioinformatic analysis highlighted numerous potential 432 pleiotropic and shared mechanisms that could potentially explain associations and patterns 433 of intermediate effect.

434

Adiposity is a well-recognised risk factor for EC^{49-51} . Our analyses found that higher BMI and WHR were positively associated with EC. In contrast, in MR analyses, we only found strong evidence that higher BMI increased EC risk. This is consistent with findings from recent MR studies where genetically elevated BMI, but not WHR, was found to be causally linked to $EC^{6,8,52,53}$. It is well-established in the literature that obesity is associated with both endometrioid and non-endometrioid EC, with stronger associations of an effect on 441 endometrioid EC, as compared to non-endometrioid EC^{6,8,52,54–60}. Interestingly, the effect of 442 BMI on non-endometrioid EC was slightly greater than endometrioid EC in our study. 443 Although rarer, non-endometrioid tumours are more aggressive and have a poorer prognosis. 444 Little is known about the etiology of non-endometrioid EC and the association with obesity 445 warrants further investigation. WHR is widely used as a proxy measure of central adiposity 446 and, notwithstanding variation in the statistical performance of analyses here and the impact 447 of measurement error and the genetic architecture of these traits on the nature of MR 448 analyses, these findings may suggest that central adiposity may be less relevant for EC risk 449 than overall adiposity. This is supported by a recent MR study which found little evidence for 450 a causal link between trunk fat ratio (proxy for abdominal adiposity) and EC but found strong 451 evidence that BMI and arm fat ratio (proxy for overall body fat) had a strong positive effect 452 on EC⁵³.

453

454 Adiposity leads to perturbations in systemic metabolism which may have an impact on EC^{16,61}. 455 In both MR and observational analyses, BMI was associated with a wide array of metabolites; 456 the effect estimates for a majority of metabolites (including HDL, VLDL, triglycerides, 457 apolipoproteins A and B, glycolysis-related metabolites and amino acids) were generally consistent in terms of direction and magnitude with previous studies^{15,41,62,63}; however, the 458 459 associations of BMI with several metabolites including LDL cholesterol, total cholesterol, 460 sphingomyelin and fatty acids were inconsistent with patterns previously observed in an MR study conducted in young adults¹⁵. For example, our study found evidence of an inverse effect 461 of BMI on LDL cholesterol which is in contrast to the previous MR study¹⁵ which supported a 462 463 positive effect of BMI. It has been suggested that the inconsistencies could be partly 464 attributable to higher prevalence of statin use in UK Biobank (22% of men and 12% of women)⁶². 465

466

467 Of the BMI-associated metabolites, 25 metabolites were also associated with either overall, 468 endometrioid or non-endometrioid EC. Our two-step and multivariable MR suggested that 469 several lipid metabolites - the majority of which were metabolite ratios - could be potential 470 intermediates between BMI and non-endometrioid EC risk. Cholesterol is an essential 471 structural component of cell membranes and altered cholesterol metabolism can drive the 472 onset and progression of cancer⁶⁴. In the circulation and within cells, free cholesterol is 473 converted to cholesteryl esters (CE) by acylCoA-cholesteryl-acyl-transferase (ACAT). 474 Numerous studies have shown that increased expression and activity of ACAT and subsequent 475 accumulation of cholesteryl esters in cancer cells is linked to the development and 476 progression of cancers, including endometrial cancer^{65,66}. We did not find strong evidence 477 that total cholesterol esters attenuated the effect of BMI on non-endometrioid EC risk in our 478 MVMR analyses. Interestingly, we found evidence that cholesteryl esters to total lipids ratio 479 in small and medium LDL were positively associated with both BMI and non-endometrioid EC 480 risk while free cholesterol to total lipids ratio in medium and large LDL were inversely 481 associated with BMI and in turn associated with reduced risk of non-endometrioid EC. These 482 metabolite ratios could represent flux through a biochemical pathway⁶⁷ and further studies 483 could be conducted to investigate their role in the development of EC.

484

485 Triglycerides, a major component of adipose tissues, are often elevated in adiposity and have 486 been suggested to drive EC development either directly or indirectly through deregulation of 487 peroxisome proliferator-activated receptors (PPARs)⁶⁸. We observed that triglycerides in LDL 488 and triglycerides to total lipids ratio in VLDL, LDL and LDL particles were positively associated 489 with both BMI and non-endometrioid endometrial cancer risk. The positive relationship 490 between triglycerides and endometrial cancer risk is consistent with several observational studies^{68–71}; however, a recent Mendelian randomization analysis study found little evidence 491 492 of a causal link between the role of triglycerides in the development of both endometrioid 493 and non-endometrioid EC⁷². To this end, further research is required to clarify the role of 494 triglycerides in non-endometrioid EC development.

495

496 Understanding how metabolites may be potential intermediates between risk factors and 497 disease outcomes is a compelling research topic. However, major challenges persist for 498 identifying instruments to proxy circulating metabolites due to the complex genetic 499 architecture of blood metabolites^{44–46}. First, owing to the high correlational structure of many 500 metabolites, instruments for metabolites are often associated with other metabolites^{46,73}. 501 Second, due to the high degree of pleiotropy (or basic biological overlap) for metabolite 502 instruments with other modifiable risk factors and disease endpoints, it is often not 503 straightforward to determine the exact molecular mechanism by which they impact the 504 outcome. Indeed, when considering whether we are reliably instrumenting the effect of BMI-

505 associated metabolites on EC, we identified other shared pathways including height and 506 several adiposity and blood cell traits that could influence associations with EC. This suggests 507 that when compared with a (hypothetically null) set of randomly selected metabolites, 508 instruments for implicated metabolites could be flagging biological pathways that may be 509 driving causal associations; however, importantly, it is difficult to distinguish whether the 510 biological pathways highlighted are due to vertical pleiotropy (i.e., the mechanism by which 511 the SNP influences the outcome is via metabolites) or horizontal pleiotropy (i.e., the SNP 512 could influence the outcome through a pathway independent of metabolites). Our approach 513 to the examination and characterisation of signal metabolites is conceptually similar to a cis-514 versus-trans MR analysis of proteins that looks to clarify inference from MR methods through 515 prior information available on the instruments in question. Using this approach, a recent 516 study⁷⁴ demonstrated that the observed relationship between small HDL particle count and 517 sepsis were - in part - driven by potential confounding between interleukin 6 (IL-6) and HDL, 518 where IL-6 signalling is the true mechanism.

519

520 This work adds to the body of evidence suggesting a causal relationship between adiposity 521 and adiposity-associated metabolites with overall, endometrioid, and non-endometrioid EC 522 risk. In our study, we focussed predominantly on lipid-based metabolites identified via ¹H-523 NMR metabolomics rather than mass spectrometry, which is not yet available at sufficient 524 scale. Mass spectrometry-based metabolomic analyses offers a broader representation of 525 metabolites beyond lipid subclasses and there is a growing body of evidence that metabolites 526 detected by mass spectrometry are altered in EC patients^{12,75}. Future metabolomic studies 527 using mass spectrometry should be conducted to comprehensively evaluate the role of 528 metabolites as intermediates between adiposity and EC.

529

Given the common shared genetic architecture, high correlation structure, and shared biology of metabolites, it is likely that a perturbation in any one metabolite does not happen in isolation. This is exemplified in recent work which has shown that the variance explained by a metabolite's instrument is often greater for another^{45,73,76}. Here, we use a naïve approach to instrumentation in a hypothesis generating analysis; however, given many metabolite instruments include only a handful of SNPs, statistical methods aiming to measure the potential effects of pleiotropy (e.g., MR-Egger) do not always lead to meaningful results. This

also applies to techniques designed to evaluate the effect of multiple correlated exposures(e.g., MVMR).

539

540 In two-sample univariable MR analyses, sample overlap can bias estimates towards the 541 confounded observational estimate (inflated type 1 error) in the presence of weak instruments in a manner proportional to the degree of overlap⁴². For our main analyses, we 542 543 likely have 100% overlap between the adiposity and metabolites GWAS and up to a maximum 544 5% overlap for both of these with the overall EC GWAS. However, given bias due to sample overlap is negligible in the presence of strong instruments⁷⁷ and that the results across 545 546 sensitivity analyses using non-overlapping samples were generally consistent with the main 547 analyses, it is unlikely that estimates from our analyses are meaningfully impacted by such 548 bias.

549

550 Another limitation is the unrepresentative nature of UK Biobank (initial response rate ~5%)⁷⁸ 551 and the potential for selection bias. Given the age of the UK Biobank participants, the 552 prevalence of statin use is high (~16% in UK Biobank vs ~11% in the general UK adult 553 population in 2014⁷⁹). For our MR analyses, we used summary-level data from the ¹H-NMR 554 metabolite GWAS conducted using data from UK Biobank. This approach limits the capacity 555 to fully explore the effects of other factors such as age and medication use (including statin 556 use and HRT), which may influence the association between adiposity traits, metabolites and 557 EC. Our analyses were limited to women of European ancestries; thus, these findings may 558 not apply to individuals of other ancestries. Furthermore, given that we used the same ¹H-559 NMR data from UK Biobank for both our MR and observational analyses examining the 560 associations between adiposity traits and metabolites, these analyses cannot be considered 561 independent. Replication of this study in other large cohort studies and in other ethnicities 562 will allow a more robust characterisation of the metabolic profile associated with adiposity 563 and the subsequent impact on EC.

564

565 **Conclusions**

566 Our study suggests that higher BMI causes a higher risk of overall and all histological subtypes 567 of EC and variation in numerous circulating metabolites. Several of these metabolites showed 568 relationships consistent with an intermediate role in the effect of BMI on non-endometrioid

- 569 EC from two-step and MVMR MR analyses; however, further bioinformatic analyses
- 570 highlighted other potential shared mechanisms that could influence the risk of EC.

571

572 **Declarations**

- 573 DP receives consulting fees from Johnson & Johnson and Novo Nordisk and payments for
- 574 lectures, presentations, and educational events from Johnson & Johnson, Medtronic, and
- 575 Novo Nordisk.
- 576 Ethics approval
- 577

578 Author contributions

- 579 MAL: conceptualization, data curation, formal analysis, investigation, methodology, project 580 administration, validation, visualization, writing (original draft preparation), writing (review &
- 581 editing)
- 582
- 583 VT: conceptualization, data curation, formal analysis, investigation, methodology, project
- administration, validation, visualization, writing (original draft preparation), writing (review &
- 585 editing)
- 586
- 587 DP: resources, supervision, writing (review & editing)
- 588
- 589 SW: writing (review & editing)
- 590
- 591 LD: writing (review & editing)
- 592
- 593 MJG: writing (review & editing)
- 594
- 595 LJC: resources, supervision, writing (review & editing)
- 596
- 597 KHW: resources, supervision, writing (review & editing)

598

599 NJT: conceptualization, resources, supervision, writing (review & editing)

600

601 Acknowledgments

We would like to express our appreciation to UK Biobank participants and staff for providing
the research community with this valuable source of data. This work used data from
application number 16391.

605

606 Code and data availability

607 Univariable MR analyses were performed using TwoSampleMR³³(version 0.4.22).; multivariable MR analyses were performed using MVMR)³⁹ (version 0.3) R package; forest 608 plots were created using ggforestplot (version 0.1)⁸⁰ R package; circos plots were created 609 610 using EpiViz^{81–83} (version 0.1) R package. All publicly available data, code, and results used in 611 this work are available GitHub: on https://github.com/mattlee821/adiposity metabolites endometrial cancer. This includes 612 613 all exposure data used in all MR analyses. The full summary statistics for BMI and WHR are 614 available GIANT from the consortium (https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT consortium data 615 616 files) and Zenodo (https://zenodo.org/record/1251813#.Yk7O25PMIUE), data files 4, 5, 7, and 617 8. The full summary statistics for the endometrial cancer GWAS are available from the 618 OpenGWAS database (https://gwas.mrcieu.ac.uk/datasets/); IDs for endometrial cancer 619 GWAS: ebi-a-GCST006464, ebi-a-GCST006465, and ebi-a-GCST006466; This can be accessed 620 (https://mrcieu.github.io/TwoSampleMR/) via the TwoSampleMR and ieugwasr 621 (http://gwas-api.mrcieu.ac.uk/) R packages or directly from OpenGWAS in GWAS-VCF 622 format⁵⁰. The full summary statistics for the ¹H-NMR metabolites will be made available at 623 the University of Bristol data repository. The individual level data used in this work is not 624 publicly available and can only be obtained from UK Biobank with an approved application.

625

626 Funding

This work was supported by the Wellcome Trust through a Wellcome Trust Investigator award to NJT (202802/Z/16/Z, 2016-2023). MAL is funded by a Medical Research Council GW4 studentship (grant number: MR/R502340/1). NJT was a Wellcome Trust Investigator (202802/Z/16/Z, 2016-2023), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical 632 Research Centre (BRC-1215-2001), the MRC Integrative Epidemiology Unit (MC UU 00011/1) 633 and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019). 634 VT, NJT, SW, LD and MG are supported by the Cancer Research UK (grant number: PRCPJT-635 May22\100028). L.J.C. was supported by N.J.T.'s Wellcome Investigator Award 636 (202802/Z/16/Z) 2016-2023, and by MC UU 00032/1 since 2023. All authors work in the 637 MRC Integrative Epidemiology Unit at the University of Bristol, which is supported by the 638 Medical Research Council (grant numbers: MC_UU_00011/1-7) and the University of Bristol. 639 KHW is supported by the University of Bristol and Cancer Research UK [grant number 640 RCCPDF\100007]. DJP has been funded by the Royal College of Surgeons of England. He 641 receives consulting fees from Johnson & Johnson and Novo Nordisk and payments for 642 lectures, presentations, and educational events from Johnson & Johnson, Medtronic, 643 and Novo Nordisk. This research was funded in whole, or in part, by the Wellcome Trust 644 [202802/Z/16/Z, 217065/Z/19/Z]. For the purpose of Open Access, the author has applied a 645 CC BY public copyright licence to any Author Accepted Manuscript version arising from this 646 submission.

647

648 Disclaimer

Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.

653

654 **Conflict of interest**

655 None declared

656

657 References

- Bray, F. *et al.* Global cancer statistics 2018: GLOBOCAN. *CA Cancer J Clin* (2018)
 doi:10.3322/caac.21492.
- 660 2. Tavassoli, F. a & Devilee, P. Classification of Tumours. Pathology and Genetics of
 661 Tumours of the Breast and Female Genital Organs. *World Health Organization* (2003).
- 662 3. Amant, F. et al. Endometrial cancer. The Lancet **366**, 491–505 (2005).
- 4. Aune, D. *et al.* Anthropometric factors and endometrial cancer risk: A systematic
 review and dose-response meta-analysis of prospective studies. *Annals of Oncology*vol. 26 Preprint at https://doi.org/10.1093/annonc/mdv142 (2015).
- 5. Smith, G. D. & Ebrahim, S. 'Mendelian randomization': Can genetic epidemiology
 contribute to understanding environmental determinants of disease? *International Journal of Epidemiology* vol. 32 Preprint at https://doi.org/10.1093/ije/dyg070 (2003).
- 669 6. Painter, J. N. *et al.* Genetic risk score mendelian randomization shows that obesity
 670 measured as body mass index, but not waist:hip ratio, is causal for endometrial cancer.
 671 *Cancer Epidemiology Biomarkers and Prevention* 25, (2016).
- 672 7. Lee, M. A. *et al.* Systematic review and meta-analyses: What has the application of
 673 Mendelian randomization told us about the causal effect of adiposity on health
 674 outcomes? *Wellcome Open Res* 7, (2022).
- 675 8. O'Mara, T. A. *et al.* Identification of nine new susceptibility loci for endometrial
 676 cancer. *Nat Commun* 9, 3166 (2018).
- Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation1. Hanahan,
 D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646–674
 (2011). Cell 144, (2011).
- Njoku, K. *et al.* Metabolomic Biomarkers for the Detection of Obesity-Driven
 Endometrial Cancer. *Cancers* vol. 13 Preprint at
- 682 https://doi.org/10.3390/cancers13040718 (2021).
- 483 11. Yang, X. & Wang, J. L. The role of metabolic syndrome in endometrial cancer: A
 484 review. *Frontiers in Oncology* vol. 9 Preprint at
- 685 https://doi.org/10.3389/fonc.2019.00744 (2019).
- 686 12. Dossus, L. *et al.* Prospective analysis of circulating metabolites and endometrial cancer
 687 risk. *Gynecol Oncol* 162, 475–481 (2021).
- Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin
 resistance and type 2 diabetes. *Nature* vol. 444 Preprint at
 https://doi.org/10.1038/nature05482 (2006).
- Rosen, E. D. & Spiegelman, B. M. What we talk about when we talk about fat. *Cell*vol. 156 Preprint at https://doi.org/10.1016/j.cell.2013.12.012 (2014).
- 693 15. Würtz, P. *et al.* Metabolic Signatures of Adiposity in Young Adults: Mendelian
 694 Randomization Analysis and Effects of Weight Change. *PLoS Med* 11, (2014).
- Kliemann, N. *et al.* Metabolic signatures of greater body size and their associations
 with risk of colorectal and endometrial cancers in the European Prospective
 Investigation into Cancer and Nutrition. *BMC Med* 19, (2021).
- Relton, C. L. & Davey Smith, G. Two-step epigenetic mendelian randomization: A
 strategy for establishing the causal role of epigenetic processes in pathways to disease. *Int J Epidemiol* 41, (2012).
- 701 18. Davey Smith, G. *et al.* STROBE-MR: Guidelines for strengthening the reporting of
 702 Mendelian randomization studies. *PeerJ Prepr* 7, (2019).
- 19. von Elm, E. *et al.* The strengthening the reporting of observational studies in
 epidemiology (STROBE) statement: Guidelines for reporting observational studies.
 International Journal of Surgery 12, (2014).

	•	
706	20.	Sudlow, C. <i>et al.</i> UK Biobank: An Open Access Resource for Identifying the Causes
707		of a Wide Range of Complex Diseases of Middle and Old Age. <i>PLoS Med</i> 12 , (2015).
708	21.	Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data.
709		<i>Nature</i> 562 , (2018).
710	22.	Collins, R. What makes UK Biobank special? The Lancet 379 , 1173–1174 (2012).
711	23.	Julkunen, H., Cichońska, A., Slagboom, P. E., Würtz, P. & Initiative, N. H. U. K. B.
712		Metabolic biomarker profiling for identification of susceptibility to severe pneumonia
713		and COVID-19 in the general nonulation <i>Flife</i> 10 e63033 (2021)
714	24	Würtz P <i>et al</i> Quantitative serum nuclear magnetic resonance metabolomics in large
715	24.	wurtz, 1. et al. Quantitative serum nuclear magnetic resonance metabolomies in large-
715		(2017)
/10	25	(2017).
/1/	25.	Pulit, S. L. <i>et al.</i> Meta-analysis of genome-wide association studies for body fat
/18		distribution in 694 649 individuals of European ancestry. <i>Hum Mol Genet</i> 28, 166–174
719		(2019).
720	26.	Soininen, P. et al. High-throughput serum NMR metabonomics for cost-effective
721		holistic studies on systemic metabolism. Analyst (2009) doi:10.1039/b910205a.
722	27.	Howie, B., Marchini, J. & Stephens, M. Genotype Imputation with Thousands of
723		Genomes. G3: Genes Genomes Genetics 1, 457–470 (2011).
724	28.	Huang, J. et al. Improved imputation of low-frequency and rare variants using the
725		UK10K haplotype reference panel. Nat Commun 6, 8111 (2015).
726	29.	Mitchell, R. Hemani, G. Dudding, T. Paternoster, L. UK Biobank Genetic Data: MRC-
727		IEU Quality Control, Version 1. (2017)
728		doi:https://doi.org/10.5523/bris.3074krb6t2fri29vh2b03x3wxi
729	30	Mitchell R Hemani G Dudding T Corbin L Harrison S P L UK Biobank Genetic
730	20.	Data: MRC-IFU Quality Control version 2
731		https://doi.org/10.5523/bris.lovaau5sxunp?cv8rcv88688v (2019)
732	31	Anderson C A <i>et al</i> Data quality control in genetic case-control association studies
733	51.	Nat Protoc (2010) doi:10.1038/nprot 2010.116
737	32	Loh P R at al Efficient Bayesian mixed-model analysis increases association power
735	52.	in large cohorte. Nat Canet (2015) doi:10.1028/ng.2100
735	22	Homoni G at al The MD Dage plotform supports systematic coursel informace across
730	55.	the human phenome. Elife 7, 224408 (2018)
151	24	Use numan phenome. Elije 7, 634406 (2016).
/30	54.	Hemani, G., Thing, K. & Davey Smith, G. Orienting the causal relationship between
/39		imprecisely measured traits using GWAS summary data. PLos Genet 13, e100/081
/40	25	(2017).
/41	35.	Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
742		instruments: effect estimation and bias detection through Egger regression. Int J
743		<i>Epidemiol</i> 44 , 512–525 (2015).
744	36.	Burgess, S. et al. Dissecting Causal Pathways Using Mendelian Randomization with
745		Summarized Genetic Data: Application to Age at Menarche and Risk of Breast
746		Cancer. Genetics 207, 481–487 (2017).
747	37.	Hartwig, F. P., Davey Smith, G. & Bowden, J. Robust inference in summary data
748		Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol
749		(2017) doi:10.1093/ije/dyx102.
750	38.	Sanderson, E., Davey Smith, G., Windmeijer, F. & Bowden, J. An examination of
751		multivariable Mendelian randomization in the single-sample and two-sample summary
752		data settings. Int J Epidemiol 48, 713–727 (2018).
753	39.	Sanderson, E., Spiller, W. & Bowden, J. Testing and correcting for weak and
754		pleiotropic instruments in two-sample multivariable Mendelian randomization. Stat
755		<i>Med</i> n/a , (2021).

756 40. Locke, A. E. et al. Genetic studies of body mass index yield new insights for obesity 757 biology. Nature 518, 197-206 (2015). Bull, C. J. et al. Adiposity, metabolites, and colorectal cancer risk: Mendelian 41. 758 759 randomization study. BMC Med 18, (2020). Burgess, S., Davies, N. M. & Thompson, S. G. Bias due to participant overlap in two-760 42. sample Mendelian randomization. Genet Epidemiol 40, (2016). 761 762 43. Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat 763 distribution. Nature 518, 187–196 (2015). 764 Gallois, A. et al. A comprehensive study of metabolite genetics reveals strong 44. 765 pleiotropy and heterogeneity across time and context. Nat Commun 10, (2019). Smith, C. J. et al. Integrative analysis of metabolite GWAS illuminates the molecular 766 45. basis of pleiotropy and genetic correlation. *Elife* 11, (2022). 767 768 46. Lotta, L. A. et al. Cross-platform genetic discovery of small molecule products of 769 metabolism and application to clinical outcomes. Nat Genet 53, (2021). 770 47. Kamat, M. A. et al. PhenoScanner V2: An expanded tool for searching human 771 genotype-phenotype associations. *Bioinformatics* **35**, (2019). 772 48. Staley, J. R. et al. PhenoScanner: A database of human genotype-phenotype 773 associations. Bioinformatics 32, (2016). 774 49. Raglan, O. et al. Risk factors for endometrial cancer: An umbrella review of the 775 literature. International Journal of Cancer vol. 145 Preprint at https://doi.org/10.1002/ijc.31961 (2019). 776 Kyrgiou, M. et al. Adiposity and cancer at major anatomical sites: Umbrella review of 777 50. 778 the literature. BMJ (Online) vol. 356 Preprint at https://doi.org/10.1136/bmj.j477 779 (2017). 780 Kalliala, I. et al. Obesity and gynaecological and obstetric conditions: umbrella review 51. 781 of the literature. BMJ 359, (2017). 782 Nead, K. T. et al. Evidence of a Causal Association between Insulinemia and 52. 783 Endometrial Cancer: A Mendelian Randomization Analysis. J Natl Cancer Inst 107, 784 (2015).785 53. Freuer, D. et al. Body fat distribution and risk of breast, endometrial, and ovarian 786 cancer: A two-sample mendelian randomization study. Cancers (Basel) 13, (2021). 787 54. Hazelwood, E. et al. Identifying molecular mediators of the relationship between body 788 mass index and endometrial cancer risk: a Mendelian randomization analysis. BMC 789 *Med* **20**, (2022). 790 55. Renehan, A. G. et al. Incident cancer burden attributable to excess body mass index in 791 30 European countries. Int J Cancer 126, (2010). 792 56. Bhaskaran, K. et al. Body-mass index and risk of 22 specific cancers: a population-793 based cohort study of 5.24 million UK adults. The Lancet 384, (2014). 794 57. Sollberger, T. L., Gavrilyuk, O. & Rylander, C. Excess body weight and incidence of 795 type 1 and type 2 endometrial cancer: The norwegian women and cancer study. Clin 796 *Epidemiol* **12**, (2020). 797 Setiawan, V. W. et al. Type i and II endometrial cancers: Have they different risk 58. 798 factors? Journal of Clinical Oncology 31, (2013). 799 Yang, H. P. et al. Endometrial cancer risk factors by 2 main histologic subtypes. Am J 59. 800 *Epidemiol* **177**, (2013). Lauby-Secretan, B. et al. Body Fatness and Cancer - Viewpoint of the IARC 801 60. 802 Working Group. New England Journal of Medicine 375, (2016). 803 61. O'Flanagan, C. H., Bowers, L. W. & Hursting, S. D. A weighty problem: Metabolic 804 perturbations and the obesity-cancer link. Hormone Molecular Biology and Clinical 805 Investigation vol. 23 Preprint at https://doi.org/10.1515/hmbci-2015-0022 (2015).

806 62. Bell, J. A. et al. Effects of general and central adiposity on circulating lipoprotein, 807 lipid, and metabolite levels in UK Biobank: A multivariable Mendelian randomization study. *The Lancet Regional Health - Europe* **21**, (2022). 808 809 Wulaningsih, W., Proitsi, P., Wong, A., Kuh, D. & Hardy, R. Metabolomic correlates 63. of central adiposity and earlier-life body mass index. J Lipid Res 60, (2019). 810 64. Riscal, R., Skuli, N. & Simon, M. C. Even Cancer Cells Watch Their Cholesterol! 811 812 Molecular Cell vol. 76 Preprint at https://doi.org/10.1016/j.molcel.2019.09.008 (2019). Omsjø, I. H. & Norum, K. R. CHOLESTEROL ESTERIFICATION IN HUMAN 813 65. 814 SECRETORY ENDOMETRIUM AND IN ENDOMETRIAL CANCER TISSUE: 815 Demonstration of Microsomal ACYL-COA-Cholesterol ACYL-transferase (ACAT) 816 Activity. Acta Obstet Gynecol Scand 64, (1985). 817 Ayyagari, V. N. et al. Evaluation of sterol-o-acyl transferase 1 and cholesterol ester 66. 818 levels in plasma, peritoneal fluid and tumor tissue of patients with endometrial cancer: 819 A pilot study. Oncol Lett 25, (2023). Petersen, A. K. et al. On the hypothesis-free testing of metabolite ratios in genome-820 67. 821 wide and metabolome-wide association studies. BMC Bioinformatics 13, (2012). 822 68. Lindemann, K., Vatten, L. J., Ellstrøm-Engh, M. & Eskild, A. Serum lipids and 823 endometrial cancer risk: Results from the HUNT-II study. Int J Cancer 124, (2009). 824 69. Trabert, B. et al. Metabolic syndrome and risk of endometrial cancer in the United 825 States: A study in the SEER-medicare linked database. *Cancer Epidemiology* Biomarkers and Prevention 24, (2015). 826 Bjørge, T. et al. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 171, 827 70. 828 (2010). 829 Seth, D. et al. Lipid profiles and the risk of endometrial cancer in the Swedish amoris 71. 830 study. Int J Mol Epidemiol Genet 3, (2012). 831 72. Kho, P. F. et al. Mendelian randomization analyses suggest a role for cholesterol in the 832 development of endometrial cancer. Int J Cancer 148, (2021). 833 Guida, F. et al. The blood metabolome of incident kidney cancer: A case-control study 73. 834 nested within the MetKid consortium. PLoS Med 18, (2021). 835 Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G. & Smith, G. D. Low 74. 836 levels of small HDL particles predict but do not influence risk of sepsis. Crit Care 27, 837 (2023).838 75. Audet-Delage, Y., Villeneuve, L., Grégoire, J., Plante, M. & Guillemette, C. 839 Identification of metabolomic biomarkers for endometrial cancer and its recurrence 840 after surgery in postmenopausal women. Front Endocrinol (Lausanne) 9, (2018). 841 76. Surendran, P. et al. Rare and common genetic determinants of metabolic individuality 842 and their effects on human health. Nat Med 28, (2022). Sadreev, I. I. et al. Navigating sample overlap, winner's curse and weak instrument 843 77. 844 bias in Mendelian randomization studies using the UK Biobank. medRxiv (2021). 845 Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Smith, G. D. Collider scope: 78. 846 When selection bias can substantially influence observed associations. Int J Epidemiol 847 47, (2018). 848 79. Curtis, H. J., Walker, A. J., MacKenna, B., Croker, R. & Goldacre, B. Prescription of 849 suboptimal statin treatment regimens: A retrospective cohort study of trends and 850 variation in English primary care. British Journal of General Practice 70, (2020). 851 80. Scheinin, I., et al. ggforestplot: Forestplots of Measures of Effects and Their 852 Confidence Intervals. 853 https://nightingalehealth.github.io/ggforestplot/index.html, https://github.com/nighting 854 alehealth/ggforestplot. (2023).

- 855 81. Lee M. A. et al. Epiviz: an implementation of Circos plots for epidemiologists.
- 856 https://github.com/mattlee821/EpiViz (2020).
- 857 82. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize implements and enhances 858 circular visualization in R . *Bioinformatics* **30**, 2811–2812 (2014).
- 859 83. Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* **32**, 2847–2849 (2016).

861

Table 1. Dasenne characteristics of UK D	IODATIK PARTICIPATILS II	iciudeu ili our study	
	N	Endometrial cancer	Controls
	(Cases/Control)	Cases	(N=215,339)
		(N=1.005)	
Continuous variables		· · · · ·	
Age at assessment (year)	1.005/215.339	59.63 (6.43)	55.83 (8.02)
Body mass index (kg/m^2) mean (SD)	979/211 756	30.33 (7.07)	27.06 (5.17)
Waist to Hin Ratio mean (SD)	1 000/214 835	0.84 (0.07)	0.82 (0.07)
Age at first birth (year)	632/145 456	24 54 (4 23)	25.38 (4.64)
Age at last birth (year)	632/145 149	29 32 (4 55)	30 35 (4 90)
Menarche age (year)	971/208 424	12 64 (1 55)	12 98 (1 62)
Categorical variables	01 1/200,424	12.04 (1.00)	12.00 (1.02)
Smoking	997/214 285		
Never	001/211,200	643 (64 49%)	129 857 (60 60%)
Previous		303 (30 39%)	65 775 (30 70%)
Current		51 (5%)	18 653 (8 70%)
Alcohol intake	1 002/214 865		10,000 (0.1 0 /0)
Daily or almost daily	1,002/214,000	143 (14 27%)	34 152 (15 89%)
3-4 times a week		160 (15 97%)	44 464 (20 69%)
Once or twice a week		252 (25 15%)	55 176 (25 82%)
1.3 times a month		130 (13 97%)	28,470(23.02%)
Special occasions only		103 (10.26%)	20,241(13.14%)
Never		145 (14 490/)	32,134(14.90%)
	1 001/014 510	115 (11.46%)	20,396 (9.49%)
Vee	1,001/214,512	00 (8 00%)	7 007 (0 640/)
res		90 (8.99%)	7,007 (2.04%)
	774/477 057	911 (91%)	206,705 (96.36%)
Education	//4/1//,85/		00.005 (00.450()
College/University degree		304 (39.28%)	68,385 (38.45%)
A levels/AS levels or equivalent		106 (13.70%)	25,756 (14.48%)
O levels/GCSEs or equivalent		215 (27.78%)	49,943 (28.08%)
CSEs or equivalent		49 (6.33%)	11,924 (6.70%)
NVQ or HND or HNC or equivalent		33 (4.26%)	9,676 (5.44%)
Other professional qualifications		67 (8.66%)	12,173 (6.84%)
Physical activity (No. of days/week of	923/202,664		
vigorous physical activity)			
0 days		394 (42.69%)	80,448 (39.70%)
1 days		156 (16.90%)	29,567 (14.59%)
2 days		148 (16.03%)	32,675 (16.12%)
3 days		106 (11.48%)	28,260 (13.94%)
4 days		46 (4.98%)	12,212 (6.02%)
5 days		36 (3.9%)	10,652 (5.26%)
6 days		12 (1.3%)	2,676 (1.32%)
7 days		25 (2.71%)	6,714 (3.31%)
Had Menopause	1,002/214,649	. ,	. ,
Yes	· ·	822 (82.04%)	126,379 (58.88%)
No		180 (17.96%)	88,270 (41.12%)
Ever used HRT	999/214,185	· /	
Yes		382 (38.24%)	78,769 (36.78%)
No		617 (61.76%)	135,416 (63.22%)

Table 1. Baseline characteristics of UK Biobank participants included in our study

kg, kilograms; m², meters squared; SD, standard deviation; p, p value; HRT, hormone replacement therapy; N, sample size

Table 2. Observational estimates of the association between adiposity measures and endometrial cancer.

Exposure	Outcome	Adjusted for age and centre		Fully adjusted	
		OR (95%Cl)	р	OR (95%CI)	р
BMI	Incident EC	1.61	7.63x10 ⁻³⁰	1.37	1.07x10⁻⁵
		(1.49, 1.75)		(1.19, 1.57)	
WHR	Incident EC	1.23	4.30x10 ⁻⁰⁷	1.15	0.03
		(1.14, 1.34)		(1.01, 1.32)	

BMI, Body mass index; WHR, waist hip ratio; EC, endometrial cancer; OR, odds ratio; CI, confidence interval; p, p value



Figure 1. Study overview.

This study has four main analyses that were performed sequentially to estimate: (**Part I**) the effect of adiposity measures on EC, (**Part II**) the effect of adiposity measures on metabolites, (**Part III**) the effect of adiposity-associated metabolites and EC, and (**Part IV**) the potential intermediate role of adiposity-associated metabolites in the relationship between adiposity and EC (identified in **Part II** and **III**). Conventional observational analyses were performed for Parts I-IV.



Figure 2. Mendelian randomization and observational estimates of the effect of BMI and WHR on endometrial cancer

The forest plot shows the estimates of the association between BMI and WHR with overall, endometrioid and non-endometrioid endometrial cancer from MR analyses (IVW method) using summary data from the Endometrial Cancer Association Consortium (ECAC) (n=12,906 endometrial cancer cases and 108,979 controls) and conventional observational analyses using individual level data from UK Biobank. Symbols represent point estimates from individual analyses. Horizontal lines represent 95% confidence intervals. Close circles represent p<0.05.



Figure 3. Mendelian randomization estimates of the effect of BMI on metabolites

The volcano plot shows the estimates of the effect of BMI on circulating metabolites from Mendelian randomization analyses. Metabolites associated with BMI at p<0.05 after correcting for multiple testing using Bonferroni correction are labelled.



Figure 4. Estimates of the causal effect of the BMI-associated metabolites on endometrial cancer risk

The forest plot shows the estimate of the causal effect of the BMI-associated metabolites and overall, endometrioid and non-endometrioid endometrial cancer based on two-sample MR (IVW method) from female-specific analyses. Only metabolites associated with endometrial cancer with a *p*<0.05 are shown in this figure. Symbols represent point estimates from individual analyses. Horizontal lines represent 95% confidence intervals. Squares represent metabolites that are positively associated with BMI and circles represent metabolites that are negatively associated with BMI.



Figure 5. Multivariable mendelian randomization estimates of the direct effect of BMI on endometrial cancer after adjustment for various BMIassociated metabolites

The forest plot shows the estimate of the direct causal effect of BMI on overall, endometrioid and non-endometrioid endometrial cancer based on multivariable MR analyses after adjustment for various metabolites that were associated with A) increased association with both BMI and endometrial cancer or B) decreased association with both BMI and endometrial cancer. Symbols represent point estimates of the direct effect of BMI on endometrial cancer after adjustment for various BMI-associated metabolites separately from multivariable MR analyses. Dotted red line represents the estimates of the indirect effect of BMI on endometrial cancer obtained from univariable IVW analyses.



Figure 6. Traits associated with genetic instruments for metabolites underlying effect of BMI on endometrial cancer

A) The blue bars represent the proportion of genetic instruments associated with the top 30 traits identified in PhenoScanner for metabolites underlying the effect of BMI on endometrial cancer relative to the negative control (grey bars). The negative control was obtained by iteratively (N=100) looking up traits associated with instruments for 25 randomly selected metabolites not underlying the association between BMI and endometrial cancer; B) the histograms represent the frequency of the number of SNPs associated with trait from the negative control analysis. The red line represents the mean of the number of SNPs associated with each trait for the negative control and the blue line represents the number of SNPs associated with the metabolites underlying the effect of BMI on endometrial cancer risk associated with each trait.